Physician profile
Danielle Turdo
NPI 1598207466
$4,759.20
in general payments reported to CMS, 2019-2025
16 companies · $3,857 in 2025
The $3,857 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.59 · 2022: $74.85 · 2023: $152 · 2024: $653 · 2025: $3,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Consulting Fee: $1,535 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,290 · Travel and Lodging: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.76 |
| Consulting Fee | $1,535.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,290.00 |
| Travel and Lodging | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,875.30 | 2024-2025 | |
| Janssen Biotech, INC. | $1,862.20 | 2021-2025 | Talvey, Rybrevant, Carvykti |
| Alexion Pharmaceuticals, INC. | $217.12 | 2023-2025 | Ultomiris |
| Incyte Corporation | $179.54 | 2024-2025 | Niktimvo, Jakafi, Niktimvo |
| Genzyme Corporation | $163.95 | 2024-2025 | |
| Amgen INC. | $148.52 | 2022-2025 | Blincyto, Kyprolis, Blincyto |
| Novartis Pharmaceuticals Corporation | $75.43 | 2023 | |
| Genentech USA, INC. | $57.47 | 2022-2025 | Polivy, Venclexta, Gazyva |
| Genmab U.S., INC. | $38.30 | 2024 | Epkinly, Tivdak |
| Astellas Pharma US INC | $30.08 | 2025 | Cresemba |
| Abbvie INC. | $24.59 | 2024 | |
| Pharmaessentia USA Corporation | $22.73 | 2023 | Besremi |
| Sobi, INC | $20.37 | 2025 | |
| Daiichi Sankyo INC. | $20.30 | 2024 | Injectafer |
| Morphosys, US INC. | $14.90 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $8.40 | 2025 | Tecvayli, Talvey, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Turdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.